The DUPIXENT Profile
TK Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients […]
Efficacy and Safety Profile
Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies […]
Appropriate Patients
Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies […]
Patient Story
Developed under the direction and sponsorship of Sanofi US and Regeneron Pharmaceuticals, Inc. Important Safety Information Full Prescribing Information INDICATION DUPIXENT® (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies […]
Efficacy Overview
Safety Profile
Real-World Results in Adults
Real Provider Videos
Real Patient Stories
Coverage and Patient Support
